synthesis [1-3]. The diphosphate derivative inhibits
Magnusen Clinical Center, NIH (Bethesda, MD, ribonucleotide reductase, thereby depleting the en-USA). dogenous deoxyribonucleotide triphosphate pools. The triphosphate derivative is incorporated into DNA Standard solutions and subsequently interferes with DNA chain elongation. Gemcitabine is deaminated to the inactive Stock solutions of dFdC, dFdU and FdC at metabolite 29,29-difluorodeoxyuridine (dFdU) by cyconcentrations of 10 mM (2.63 mg / ml), 7.57 mM (2 tidine deaminase. Gemcitabine is used clinically to mg / ml) and 10 mM (2.44 mg / ml), respectively, treat a variety of solid tumors, particularly panwere prepared in water; aliquots were stored at creatic, bladder and non-small cell lung cancers.
230 8C. Calibration standards were prepared by Preclinical studies conducted in our laboratory appropriate dilutions of the dFdC stock solutions suggested that the combination of dFdC for 4 h with water to generate 103 calibration standards at followed by a 24-h exposure to 5-fluoro-29-deoxyconcentrations ranging between 5 and 1500 mM; uridine (FdU) resulted in more than additive cytotoxaliquots were stored at 230 8C; dilutions of the icity and enhanced DNA damage in a human colon dFdU stock solutions with water generated 103 cancer cell line [4] . Therefore, a Phase I trial of calibration standards ranging from 5 to 2270 mM. weekly dFdC followed by a 24-h infusion of FdU Plasma calibration standards were made by adding was designed. To permit determination of the plasma 50 ml of a 103 calibration standard solution to 0.5 levels of dFdC and dFdU in patient samples, a ml of plasma to give final concentrations upon reversed-phase HPLC assay was developed.
reconstitution of the extracted plasma sample that ranged between 0.5 and 150 mM for dFdC or 0.5 and 227 mM for dFdU. Fifty microliters of 250 mM FdC or 20 ml of 1 mM FdC was added to 0.5 ml plasma Experimental conditions to give a final concentration of 25 or 40 mM (see Section 3.1).
Chemicals
Sample preparation The commercial formulation of gemcitabine hydrochloride (each vial contains 200 mg of gemStandard curves were prepared in pooled plasma citabine as the free base, 262.9 g / mol) was purwhich was placed on ice immediately upon thawing. chased from Eli Lilly and Company (Indianapolis, Aliquots of 0.5-ml test plasma were placed in 12375 IN, USA). dFdU was generously provided by Lilly mm glass tubes on ice; calibration standards and 20 Research Laboratories though a material transfer ml of 1 mM internal standard were added. Glacial agreement with the National Cancer Institute (NCI).
acetic acid (50 ml) was added to decrease hydrogen FdC (HPLC internal standard), was purchased from bonding between the nucleosides and proteins. After Sigma (St Louis, MO, USA). Tetrahydrouridine the addition of 1 ml of acetonitrile, the samples were (THU), an inhibitor of cytidine deaminase, was vortex-mixed. Following centrifugation at 800 g for provided by the Drug Synthesis and Chemistry 15 min at 4 8C, the supernatant was removed. To Branch, Developmental Therapeutics Program, Diviimprove the recovery (see Section 3.2), 1 ml of sion of Cancer Treatment and Diagnosis, NCI, acetonitrile was added to the precipitate, the sample National Institutes of Health (NIH), Bethesda, MD, was vortex-mixed followed by repeat centrifugation. USA [5] . Glacial acetic acid (analytic reagent (AR)
The supernatants were combined, and the sample grade) and sodium acetate (AR grade) were from was evaporated to dryness using filtered compressed  Mallinckrodt (Paris, KY, USA). HPLC grade water, air in a 42 8C water bath in a Zymark TurboVap methanol and acetonitrile were from Fisher (Fair (Hopkinton, MA, USA) and stored at 230 8C. On Lawn, NJ, USA). All other chemicals were AR the day of analysis, the residue was re-suspended in grade. Pooled donor plasma was obtained from the 0.5 ml HPLC water, incubated for 5 min in a 37 8C Department of Transfusion Medicine, Warren G.
water bath, and then clarified by centrifugation at 12 000 g for 10 min at 20 8C. The resultant supernareturn to 100% A and re-equilibration for 6 min. tant was filtered though a 1-ml syringe fitted with a FdC, dFdC and dFdU were monitored at wave-GHP 13-mm Acrodisc, 2-mm pore size, with minilengths of 282, 269 and 258 nm, respectively. spike outlet (Pall Gelman Laboratory, Ann Arbor, MI, USA). An aliquot of each sample was placed in Calculations 250-ml low volume glass inserts placed in 4-ml glass vials (Waters, Milford, MA, USA) and loaded into a
The ratios of the peak heights of dFdC or dFdU to 48-position carousel tray. The injection volume was FdC were calculated, which were then plotted versus 190 ml. The residuals of the reconstituted samples the nominal total amount of dFdC or dFdU in the were stored at 230 8C in the event that repeat sample. The data were fitted using least squares injection was needed. Because the calibration stanlinear regression with a weighting factor of 1 /y, not dards were prepared in pre-chilled plasma on ice, the including the origin, using SigmaPlot 2001 (SPSS, inclusion of THU (final concentration 1 mM) during Chicago, IL, USA). Analyte concentrations were their preparation did not affect either the recovery or determined using the calibration lines thus generated. peak heights of the analytes or internal standard.
Blood samples from patients receiving 1000 mg / Recovery 2 m of dFdC were obtained using 10-ml heparinized tubes containing 10 nmol THU. The blood collection Plasma samples were prepared in triplicate contubes were immediately placed on ice until centrifutaining six concentrations ranging from 0.5 to 100 gation at 1000 g for 10 min at 4 8C. Aliquots of mM of dFdC and dFdU; each sample contained a plasma were stored at 270 8C until analysis. Twenty fixed concentration of FdC (25 mM). Non-treated microliters of 1 mM FdC were added to 0.5-ml standards were samples in which the same conaliquots of plasma, and the samples were then centration of the internal standard, dFdC or dFdU prepared as described above.
were prepared in water and not subjected to the precipitation procedure. The percent absolute reHigh-performance liquid chromatography with covery was defined as the (peak height of the photodiode array detection precipitated plasma standard4peak height of the non-treated standard)3100%. The Waters chromatographic system (Milford, MA, USA) was used consisting of a 600E MultiValidation solvent Delivery System, a 717 plus Autosampler set at 4 8C, a 996 Photodiode Array Detector and an
Concentrations of dFdC and dFdU were deterin-line vacuum degasser. A Columbusீ C column 18 mined by three calibration curves run over a 3-week (5-mm particle size, 110 A pore size, 15034.6 mm) period to compare the observed with the theoretical was employed for the separations (Phenomenex, concentration. To determine within-run variation, Torrance, CA, USA). The pre-column was a Waters triplicate samples at six different concentrations of C Nova-Pak Sentry guard column (4-mm particle 18 dFdC and dFdU were prepared in human plasma, size). A Micron Millennia computer (Nampa, ID, and the samples were injected on the same day. USA) was used to acquire data and perform the Between-run variation was determined by injecting initial data analysis using Millenium 32 software triplicate samples prepared at three different conversion 3.2 (Waters).
centrations on three separate occasions. HPLC solvent A was 50 mM sodium acetate (pH 5.0) with 2% (v / v) methanol; solvent B was the same buffer with 10% (v / v) methanol. Total flowStability of samples rate was 1.5 ml / min and the column was at ambient temperature. The following program was run: 100%
The stability of the stock solutions of dFdC, dFdU A for 17 min, a linear gradient of 100% A to 100%
and FdC was tested by preparing three concen-B over 14 min, 100% B for 2 min, and immediate trations of the compounds in water, and analyzing an aliquot immediately and after storage at room tema second acetonitrile precipitation improved the perature and at 230 8C.
absolute recoveries by about 17% over that achieved with a single precipitation with 1 ml acetonitrile; recovery with two sequential 1-ml precipitations was Analysis of patient plasma samples also greater than a single precipitation with 2 ml acetonitrile (data not shown). With the sample prepaPatients were participating in an Institutional ration described herein, the overall recovery of all Review Board-approved Phase I clinical trial involvthree analytes from 0.5 ml plasma was $70% for ing dFdC given as either a 1-or 2-h infusion dFdC, $68% for FdC, and $82% for dFdU (Table  followed by 
six standard concentrations of dFdC and dFdU with a fixed FdC concentration that were examined over a 3-week period are shown in Table 2 . The percent Results coefficients of variation (% CV) for dFdC were below 3% at concentrations $5 mM, and were below High-performance liquid chromatography 10.2% for 1 and 0.5 mM. There was greater variability with dFdU: the %CV was 22.2% with 0.5 FdC, dFdC and dFdU were resolved from endogmM, but was below 7% for higher concentrations enous compounds with resulting retention times of with the exception of 5 mM (%CV 11.5%). The 2 13.660.5, 18.161.1 and 29.060.6 min, respectively. average r values for the three calibration curves dFdC and dFdU were monitored at their optimal UV were above 0.998 for both dFdC and dFdU. wavelengths, 269 and 258 nm, respectively, under Within-run variation was assessed using six conthe experimental conditions as determined by speccentrations of dFdC and dFdU with fixed concentral analysis using the photodiode array detector.
trations of FdC (25 mM) and THU (1 mM) prepared Because an endogenous peak (that was not present in triplicate. The results of within-run variation were when FdC stock solution was directly injected) determined by comparing the peak heights for dFdC, eluted shortly after FdC, we compensated by increasdFdU and FdC for these nine separate samples ing the amount of the internal standard from 25 to 40 injected into the HPLC system on the same day. The mM, and monitoring the peak height at 282 nm.
coefficients of variation ranged from 1.1 to 6.0% for These measures provided a greater peak height for dFdC, and were ,4.3% for dFdU and FdC (Table  FdC and allowed baseline resolution between FdC 3). Assessment of between-run variability was carand the adjacent endogenous peak (Fig. 2) . THU is ried out subsequently using concentrations of dFdU not detectable under the conditions used.
and dFdC that would encompass the expected plasma concentrations taken from patients during the 1-to Recovery 2-h dFdC infusion. The coefficients of variation were #5.1% for three compounds (Table 4) . Absolute recovery of FdC, dFdC and dFdU from plasma was compared to non-extracted samples prepared in water under identical concentrations. In Linearity preliminary studies, it was determined that the recovery was about 10% greater when the samples
The assay was linear between 0.5 and 150 mM were filtered though a GHP 0.2-mm syringe filter (0.13-39.4 mg / ml) for dFdC and 1 to 227 mM compared to the use of a PVDF filter. Application of (0.26-60.0 mg / ml) for dFdU. Triplicate samples of internal standard (fixed concentration of 25 mM) and calibration standards were prepared in both plasma and water. The plasma was subjected to the sample preparation described in Section 2, whereas aliquots of the standards prepared in water were directly injected into the HPLC without further processing. The data are from three calibration curves in human plasma done over a 3-week period. The internal standard concentration was 40 mM. The data are from samples prepared in triplicate and injected during the same HPLC run.
Stability month, and at both 4 8C and room temperature for at least 1 week (data not shown). It has been reported that both gemcitabine and dFdU are stable for at least 21 months at 270 8C in Testing of patient plasma samples THU-treated human plasma, and that both analytes were unaffected by three freeze-thaw cycles [8] .
Plasma dFdC and dFdU concentrations were deTherefore, we did not repeat this analysis. In the termined as part of a Phase I trial of weekly dFdC current study, stock solutions of 1 mM FdC, 1 mM, followed by infusional FdU. The plasma concen-2 100 and 10 mM dFdC, and 7.57 mM, 378.5 and trations for six patients each receiving 1000 mg / m 37.85 mM dFdU were stable at 230 8C for at least 1 dFdC as either a 1-or 2-h infusion are shown in The data are from samples prepared in human plasma in triplicate and injected on three different days.
acetate, or acetonitrile. We found that liquid-liquid extraction with two sequential acetonitrile applications yielded the best recovery. Several studies have been published that describe analysis of dFdC and dFdU in plasma samples obtained from cancer patients receiving gemcitabine [6] [7] [8] [9] [10] . However, only a few employed an internal standard and provided sufficient information to ensure method reproducibility [6, 9] . The first validated assay reported from researchers at Lilly Research Laboratories used normal-phase HPLC with an Alltechீ amino column [6] . The procedure required sequential liquid-liquid extraction using both isopropanol and ethyl acetate followed by concentration to dryness; the reconstituted residue was then filtered An additional published method used acetonitrile precipitation for sample preparation, and an isocratic 3. There were no interfering endogenous peaks in the mobile phase of 15 mM ammonium acetate, pH 5.0, pre-therapy samples under the conditions used. In all and acetonitrile (97.5:2.5, v / v) for 47 min followed patients, dFdC and dFdU were detected at the by a linear increase to 15 mM ammonium acetate, planned sampling times. The dFdC levels were pH 5.0, and acetonitrile (95:5, v / v) over 5 min [9] . similar at 30, 40 and 50 min in patients receiving a
The latter solvent was run isocratically for 10 min 1-h infusion, and at 90 and 105 min in those followed by a linear return over 5 min to initial receiving a 2-h infusion, suggesting the drug was at conditions. The column was allowed to equilibrate or near steady-state. The average plasma levels for for 10 min prior to the next injection, for an overall all time points for the 1-h infusion, 30.7 mM, was cycle time of 77 min to resolve dFdC, dFdU and the about twofold higher than that observed with the 2-h internal standard, 29,29-difluorodeoxythymidine. infusion, 15.2 mM. In contrast, the dFdU levels
The current method employs reversed-phase appeared to be increasing throughout the infusion, HPLC that offers a shorter cycling time (39 min), and were on average 3.2-and 7.6-fold higher than partly due to the selection of the internal standard the corresponding dFdC levels at the 50-and 105-FdC, which elutes sooner than dFdC and has similar min sampling times after the start of a 1-and 2-h recovery. This method has proven useful in the infusion, respectively. This observation is consistent analysis of samples from patients receiving dFdC with a longer half-life for dFdU, which is cleared by given as a 1-or 2-h infusion weekly for 3 of 4 renal excretion, as opposed to the predominantly weeks. By using a smaller volume of plasma (0.1-metabolic clearance of dFdC. 0.2 ml), the methodology described herein can also be employed in the analysis of samples obtained during a 30-min infusion of dFdC. Discussion
In the process of developing the current method, R eferences we evaluated several methods for sample preparation, including solid-phase extraction using different 
